Biosimilars – Forecast – Nephrology
In 2022, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $3.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2022-2032 forecast period, biosimilars of Aranesp / Nesp (darbepoetin alfa) and Mircera (methoxy polyethylene glycol-epoetin beta) will enter these markets, alongside currently available epoetin alfa biosimilars, further increasing the need for companies to set competitive pricing to either gain or maintain ESA patient shares. We present our ESA forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
